Cargando…

From circRNAs to fusion circRNAs in hematological malignancies

Circular RNAs (circRNAs) represent a type of endogenous noncoding RNA generated by back-splicing events. Unlike the majority of RNAs, circRNAs are covalently closed, without a 5′ end or a 3′ poly(A) tail. A few circRNAs can be associated with polysomes, suggesting a protein-coding potential. CircRNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Babin, Loelia, Andraos, Elissa, Fuchs, Steffen, Pyronnet, Stéphane, Brunet, Erika, Meggetto, Fabienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663548/
https://www.ncbi.nlm.nih.gov/pubmed/34747369
http://dx.doi.org/10.1172/jci.insight.151513
_version_ 1784613663128158208
author Babin, Loelia
Andraos, Elissa
Fuchs, Steffen
Pyronnet, Stéphane
Brunet, Erika
Meggetto, Fabienne
author_facet Babin, Loelia
Andraos, Elissa
Fuchs, Steffen
Pyronnet, Stéphane
Brunet, Erika
Meggetto, Fabienne
author_sort Babin, Loelia
collection PubMed
description Circular RNAs (circRNAs) represent a type of endogenous noncoding RNA generated by back-splicing events. Unlike the majority of RNAs, circRNAs are covalently closed, without a 5′ end or a 3′ poly(A) tail. A few circRNAs can be associated with polysomes, suggesting a protein-coding potential. CircRNAs are not degraded by RNA exonucleases or ribonuclease R and are enriched in exosomes. Recent developments in experimental methods coupled with evolving bioinformatic approaches have accelerated functional investigation of circRNAs, which exhibit a stable structure, a long half-life, and tumor specificity and can be extracted from body fluids and used as potential biological markers for tumors. Moreover, circRNAs may regulate the occurrence and development of cancers and contribute to drug resistance through a variety of molecular mechanisms. Despite the identification of a growing number of circRNAs, their effects in hematological cancers remain largely unknown. Recent studies indicate that circRNAs could also originate from fusion genes (fusion circRNAs, f-circRNAs) next to chromosomal translocations, which are considered the primary cause of various cancers, notably hematological malignancies. This Review will focus on circRNAs and f-circRNAs in hematological cancers.
format Online
Article
Text
id pubmed-8663548
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-86635482021-12-15 From circRNAs to fusion circRNAs in hematological malignancies Babin, Loelia Andraos, Elissa Fuchs, Steffen Pyronnet, Stéphane Brunet, Erika Meggetto, Fabienne JCI Insight Review Circular RNAs (circRNAs) represent a type of endogenous noncoding RNA generated by back-splicing events. Unlike the majority of RNAs, circRNAs are covalently closed, without a 5′ end or a 3′ poly(A) tail. A few circRNAs can be associated with polysomes, suggesting a protein-coding potential. CircRNAs are not degraded by RNA exonucleases or ribonuclease R and are enriched in exosomes. Recent developments in experimental methods coupled with evolving bioinformatic approaches have accelerated functional investigation of circRNAs, which exhibit a stable structure, a long half-life, and tumor specificity and can be extracted from body fluids and used as potential biological markers for tumors. Moreover, circRNAs may regulate the occurrence and development of cancers and contribute to drug resistance through a variety of molecular mechanisms. Despite the identification of a growing number of circRNAs, their effects in hematological cancers remain largely unknown. Recent studies indicate that circRNAs could also originate from fusion genes (fusion circRNAs, f-circRNAs) next to chromosomal translocations, which are considered the primary cause of various cancers, notably hematological malignancies. This Review will focus on circRNAs and f-circRNAs in hematological cancers. American Society for Clinical Investigation 2021-11-08 /pmc/articles/PMC8663548/ /pubmed/34747369 http://dx.doi.org/10.1172/jci.insight.151513 Text en © 2021 Babin et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Babin, Loelia
Andraos, Elissa
Fuchs, Steffen
Pyronnet, Stéphane
Brunet, Erika
Meggetto, Fabienne
From circRNAs to fusion circRNAs in hematological malignancies
title From circRNAs to fusion circRNAs in hematological malignancies
title_full From circRNAs to fusion circRNAs in hematological malignancies
title_fullStr From circRNAs to fusion circRNAs in hematological malignancies
title_full_unstemmed From circRNAs to fusion circRNAs in hematological malignancies
title_short From circRNAs to fusion circRNAs in hematological malignancies
title_sort from circrnas to fusion circrnas in hematological malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663548/
https://www.ncbi.nlm.nih.gov/pubmed/34747369
http://dx.doi.org/10.1172/jci.insight.151513
work_keys_str_mv AT babinloelia fromcircrnastofusioncircrnasinhematologicalmalignancies
AT andraoselissa fromcircrnastofusioncircrnasinhematologicalmalignancies
AT fuchssteffen fromcircrnastofusioncircrnasinhematologicalmalignancies
AT pyronnetstephane fromcircrnastofusioncircrnasinhematologicalmalignancies
AT bruneterika fromcircrnastofusioncircrnasinhematologicalmalignancies
AT meggettofabienne fromcircrnastofusioncircrnasinhematologicalmalignancies